Trust Signals
Every claim on this page is graded by evidence type. Where the evidence is animal-only, we say so. Where human data exists, we name the trial size. We do not inflate confidence to sell product. A skeptical psychiatrist should find nothing here they need to retract.
Key Takeaways
- Selank, a synthetic tuftsin-derived heptapeptide, is the only peptide on this list with any published human clinical data for anxiety-depression; trial sizes have been under 60 participants.
- BPC-157 produces antidepressant-like behavior in rodent forced-swim tests via proposed dopamine D2 receptor upregulation, but has zero published human RCTs for depression.
- No peptide covered here has FDA approval or has completed a Phase III RCT for any depressive disorder.
- SSRIs carry a number-needed-to-treat of roughly 7 to 8 for response (Cipriani et al., Lancet 2018, n = 116,477); no peptide has equivalent data to compare against this benchmark.
- Reconstituted peptide solutions degrade meaningfully over days to weeks at refrigerator temperature; lyophilized powder stored frozen is considerably more stable.
Direct Answer: What Is the Best Peptide for Depression?
Selank holds the strongest evidence base for depression-adjacent conditions, backed by small human trials in anxiety-depression overlap. BPC-157 has compelling animal mechanistic data. No peptide is proven effective for clinical depression in humans. If you are managing a diagnosed depressive disorder, an approved pharmacotherapy has thousands of times more safety and efficacy data than any research peptide.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
Evidence Ledger: All Major Claims Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Selank reduces anxiety-depression symptoms in humans | Small human RCTs (n under 60, Russian registry) | Positive, modest | Low |
| BPC-157 produces antidepressant behavior in rodents | Animal (rodent forced-swim, tail-suspension) | Positive in animals | Very Low (no human translation) |
| Semax elevates BDNF in animal models | Animal and in-vitro | Positive in animals | Very Low |
| Selank modulates GABA-A activity | Mechanism, electrophysiology studies | Positive (anxiolytic direction) | Low to Moderate for mechanism; Low for clinical outcome |
| Epithalon normalizes circadian rhythm relevant to seasonal depression | Animal, in-vitro | Directional, speculative | Very Low |
| SSRIs are effective for major depressive disorder | Multiple large RCTs; Cipriani et al. 2018 meta-analysis (n = 116,477) | Positive, clinically meaningful | High |
| Ketamine (esketamine) produces rapid antidepressant response | Multiple RCTs, FDA approval 2019 | Positive, rapid onset | High |
The Ranked List: 5 Peptides for Depression, Honest Assessment
1. Selank (Rank: Best Available Evidence)
Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Russian clinical work, primarily registered in the Russian pharmaceutical system and published in journals such as Eksperimental'naya i Klinicheskaya Farmakologiya, tested Selank against benzodiazepines for generalized anxiety disorder and mixed anxiety-depression. Sample sizes were small (most under 60 participants) and blinding quality is difficult to verify by Western standards. That said, it remains the only peptide on this list with any controlled human data for mood disorders.
Proposed mechanism: GABA-A positive modulation, enkephalin-degrading enzyme inhibition, and BDNF upregulation. Administered intranasally, bypassing most first-pass metabolism, which improves CNS delivery compared to oral routes.
Honest caveat: Positive small trials in one research system do not establish efficacy. Publication bias is likely. This should be read as preliminary signal, not proof.
2. BPC-157 (Rank: Strong Animal Data, No Human Translation Yet)
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a gastric protein. Rodjak, Sikiric, and colleagues at the University of Zagreb have published extensively on its effects in rodent models of depression, including forced-swim tests and corticosterone-induced anhedonia models. Proposed antidepressant mechanisms include upregulation of dopamine D2 receptors in the ventral tegmental area and nucleus accumbens, restoration of dopaminergic signaling disrupted by stress, and modulation of the nitric oxide system. BDNF elevation has also been proposed.
Honest caveat: Rodent forced-swim tests are a notoriously poor predictor of human antidepressant response. Most compounds that pass this test fail in humans. BPC-157's animal data is interesting; its human relevance for depression is unestablished.
3. Semax (Rank: Cognitive Evidence, Mood Evidence Indirect)
Semax is a synthetic analogue of ACTH 4-7 with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It has the best evidence for cognitive function and neuroprotection (registered in Russia for stroke and cognitive decline). Its mood relevance is primarily theoretical: ACTH fragments influence limbic circuits, and Semax elevates BDNF in animal models. There are no published human RCTs for depression as a primary endpoint.
Honest caveat: Cognitive improvement and antidepressant action are distinct. Attributing antidepressant effect to Semax based on BDNF elevation is two inferential steps removed from clinical outcome data.
4. Dihexa (Rank: Mechanistic Interest, Negligible Clinical Evidence)
Dihexa is an angiotensin IV analogue developed at Washington State University, with published animal data showing synaptogenic activity roughly described as orders of magnitude more potent than BDNF in some in-vitro assays (McCoy et al., Washington State research). Since BDNF deficiency is a leading hypothesis in depression pathophysiology, this has attracted attention. There is no published human clinical data for any indication. Long-term safety is completely unknown.
Honest caveat: Extreme potency in in-vitro assays does not translate straightforwardly to safe clinical use. Unknown toxicology at this stage is a serious limitation.
5. Epithalon (Rank: Speculative for Depression)
Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin from the pineal gland. Its primary evidence base concerns telomerase activation and longevity endpoints in animal models. The circadian-normalization hypothesis, relevant to seasonal affective disorder, is speculative. No published human RCTs for depression or any mood disorder exist.
Honest caveat: Placing Epithalon on a depression list is primarily driven by theoretical extrapolation from pineal biology. The honest confidence rating is very low.
Mechanism With Numbers: What These Peptides Actually Do
Selank and GABA-A: Electrophysiology studies have shown Selank enhances GABA-A receptor chloride current, producing an anxiolytic effect directionally similar to benzodiazepines but without confirmed receptor downregulation at studied doses in animals. It also appears to inhibit enzymes that degrade endogenous enkephalins, increasing endogenous opioid tone. In small human trials, Hamilton Anxiety Rating Scale reductions were statistically significant versus placebo, though the absolute score changes were modest.
BPC-157 and dopamine: Sikiric's group demonstrated that BPC-157 could restore rearing behavior and locomotion in rats with 6-OHDA-induced dopamine depletion, a model of Parkinsonism and anhedonia. The proposed mechanism involves direct upregulation of D2 receptor expression in the mesolimbic pathway. Nitric oxide synthase modulation has also been cited as a contributing pathway.
What this does NOT prove: Receptor upregulation in a dopamine-depleted rodent does not demonstrate the peptide will have clinically meaningful antidepressant effects in humans with heterogeneous major depressive disorder. The step from receptor change to behavioral change to human symptom change involves multiple unvalidated translations.
What Most Pages Get Wrong About Peptides for Depression
Most peptide blogs present the rodent forced-swim test as near-equivalent to a human clinical trial. It is not. The forced-swim test (FST) has produced thousands of compounds with apparent antidepressant activity in rodents. The vast majority failed when translated to human trials. The FST remains a useful early screening tool, not a proof of efficacy.
Second: pages rarely address the blood-brain barrier crossing question honestly. Most peptides are hydrophilic and large enough that systemic injection does not guarantee CNS delivery. Intranasal routes (used for Selank and Semax) improve brain delivery, but bioavailability data specific to these peptides in humans is not robustly published. Claims of CNS effect following subcutaneous injection should be viewed with skepticism unless supported by pharmacokinetic data.
Third: the Russian clinical literature on Selank and Semax is real but limited by methodology and reporting standards that do not consistently meet ICH guidelines. This does not mean the data is fabricated, but it means confidence should be tempered.
The Chemistry Behind the Rules: Why Peptides Degrade
Peptides are chains of amino acids linked by amide (peptide) bonds. These bonds are susceptible to hydrolysis, which accelerates with heat, extremes of pH, and oxidizing conditions. Once a lyophilized peptide is reconstituted in water, the degradation clock starts. Refrigeration (2 to 8 degrees Celsius) slows but does not stop hydrolysis. Repeated freeze-thaw cycles introduce mechanical stress on the peptide structure and can accelerate aggregation and fragmentation.
Specific degradation pathways relevant to these peptides include: asparagine deamidation (asparagine residues spontaneously deamidate to aspartate, altering the peptide sequence and potentially activity), methionine oxidation (relevant to Semax, which contains methionine at position 1), and disulfide scrambling in peptides containing cysteine residues.
Practical rule: if a reconstituted peptide solution has changed color, become cloudy, or developed particulates, it should not be used. A degraded peptide is not merely less potent; it may contain breakdown products with unknown activity.
Honest Head-to-Head: Peptides vs. Approved Treatments
| Compound | Human RCT Data for Depression | Regulatory Status | Known Side Effect Profile | Onset | Confidence |
|---|---|---|---|---|---|
| SSRIs (e.g., sertraline) | Yes, large meta-analyses (Cipriani 2018, n = 116,477) | FDA approved | Well-characterized (sexual, GI, withdrawal) | 2 to 6 weeks | High |
| Esketamine (Spravato) | Yes, multiple Phase III RCTs | FDA approved (treatment-resistant depression) | Dissociation, blood pressure changes, abuse potential | Hours to days | High |
| Selank | Small trials (n under 60), Russian registry | Registered drug in Russia, research chemical in US | Largely unknown long-term; mild fatigue reported | Days to weeks (claimed) | Low |
| BPC-157 | None for depression | Research chemical | Unknown | Unknown | Very Low |
| Semax | None for depression | Registered drug in Russia, research chemical in US | Largely unknown long-term | Unknown | Very Low |
The honest conclusion from this table: Peptides do not currently compete with approved antidepressants on evidentiary grounds. The interest in them is driven by mechanistic novelty and dissatisfaction with existing treatments, not by data showing superiority or equivalence.
Operational and Label Literacy: How to Evaluate What You Are Buying
Certificate of Analysis (COA): Any reputable research peptide supplier should provide a COA from a third-party analytical laboratory showing: HPLC purity (look for 98 percent or greater for research use), mass spectrometry confirmation of molecular weight matching the expected peptide, and absence of common contaminants including bacterial endotoxins (LAL test result). A COA from the supplier's own internal lab is weaker evidence than one from an independent laboratory.
Reconstitution math for Selank: Selank is typically supplied as lyophilized powder in vials. A common research supply is 5 mg per vial. If reconstituted with 2 mL of bacteriostatic water, the resulting solution is 2.5 mg per mL (2,500 mcg per mL). A nasal spray delivering 100 mcg per spray requires careful dilution to achieve this concentration in an appropriate delivery device. Document every reconstitution date.
Storage signal: Lyophilized sealed vials should be stored at minus 20 degrees Celsius for long-term storage. Reconstituted solutions should be refrigerated at 2 to 8 degrees Celsius and used within a timeframe consistent with your supplier's guidance, typically one to three weeks. Do not store reconstituted peptides at room temperature for extended periods.
Red flags on a label or product listing: No third-party COA available, molecular weight not stated, vague concentration claims (e.g., "highly concentrated"), claims of clinical efficacy for depression or other diagnosed conditions (this would constitute an unapproved drug claim), no lot number or batch traceability.
Frequently Asked Questions
What is the best peptide for depression right now?
Based on the current evidence hierarchy, Selank has the most human clinical data for anxiety-depression overlap, followed by BPC-157 for its BDNF and dopaminergic mechanisms studied in animals. Neither has completed large Phase III RCTs. No peptide has FDA approval for depression.
Has any peptide been tested in human clinical trials for depression?
Selank has been evaluated in small Russian clinical trials for generalized anxiety disorder and mixed anxiety-depression, with sample sizes typically under 60 participants. Semax has similar small-trial data. Neither trial size nor methodology meets the standard required for Western regulatory approval.
Can BPC-157 help with depression?
BPC-157 shows antidepressant-like effects in rodent forced-swim and tail-suspension tests, with proposed mechanisms involving dopamine receptor upregulation and BDNF elevation. There are no published human RCTs for depression specifically. Evidence is animal-grade only.
How does Selank work for anxiety and depression?
Selank is a synthetic heptapeptide derived from tuftsin. It modulates GABA-A receptor activity, increases brain BDNF, and appears to slow enkephalin degradation. In small human trials it reduced Hamilton Anxiety Scale scores. Its antidepressant mechanism is less well characterized than its anxiolytic one.
Is Semax the same as Selank?
No. Semax is a synthetic ACTH 4-7 analogue with cognitive and neuroprotective properties. Selank is a tuftsin-derived anxiolytic. They are sometimes co-administered in Russian clinical practice, but they have distinct receptor profiles and different primary evidence bases.
What about Epithalon or other pineal peptides for depression?
Epithalon (Epitalon) is a tetrapeptide with mostly animal and in-vitro longevity data. Its proposed role in circadian rhythm normalization could theoretically help seasonal depression, but there are no published human RCTs for any mood disorder. Evidence is very low quality.
Can you stack peptides for depression?
Selank plus Semax is a common research stack. There is no published human safety or efficacy data on combined peptide protocols for depression. Stacking multiplies unknown interaction risks and makes it impossible to attribute effect or adverse event to any single compound.
What are the real risks of using research peptides for depression instead of approved medications?
Key risks include: unknown long-term safety, no standardized dosing, purity variability from unregulated suppliers, potential delay of effective treatment, and the absence of pharmacovigilance data. Depression carries serious mortality risk; substituting unproven compounds for evaluated treatments is a clinically significant decision.
How stable are these peptides once reconstituted?
Most research peptides degrade meaningfully within days to a few weeks once reconstituted in bacteriostatic water and refrigerated. Selank nasal drops degrade faster at room temperature. Lyophilized powder in sealed vials is stable considerably longer when kept frozen. Specific half-life data for these exact peptides in reconstituted form is not reliably published.
Do peptides for depression require a prescription?
In the United States, Selank, Semax, and BPC-157 are not FDA-approved drugs. They occupy a regulatory grey area, sold as research chemicals. In Russia and some Eastern European countries, Selank and Semax are registered pharmaceutical drugs requiring a prescription. Legal status varies by jurisdiction.
How do research peptides compare to SSRIs for depression?
SSRIs have decades of RCT data, defined effect sizes (NNT roughly 7 to 8 for response vs placebo in meta-analyses), known side effect profiles, and regulatory approval. Research peptides have none of these. The honest answer is that peptides cannot currently be compared to SSRIs on equal footing because the evidence bases are not equivalent.
Sources
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (including short bowel syndrome) and wound healing. Inflammopharmacology. 2006;14(5-6):214-221. (Representative publication from the Zagreb BPC-157 research group; consult PubMed for full list.)
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new anxiolytic drug selank in the treatment of generalized anxiety disorder. Bulletin of Experimental Biology and Medicine. 2008;146(3):293-298.
- Kolomin T, Shadrina M, Slominsky P, et al. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine. 2013;4(4):223-252.
- McCoy AT, Benoist CC, Otto NM, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013;344(1):141-154.
- Grigoriev VV, Ivanova TA, Zamoyski VL, et al. Selank effects on GABA-A receptor channels in hippocampal neurons. Eksperimental'naya i Klinicheskaya Farmakologiya. 2012;75(12):8-12.
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592.
- FDA. Spravato (esketamine) prescribing information. 2019. Available at: fda.gov.
- Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. 1995. (Context for forced-swim test limitations.)